In EGFR-mutated NSCLC, osimertinib, a third-generation EGFR TKI, has remained the standard first-line treatment since 2018, and demonstrated a robust IC ORR of 91% in the FLAURA trial [65]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.